Status:
COMPLETED
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
Eligibility Criteria
Inclusion
- Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD
Exclusion
- History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
843 Patients enrolled
Trial Details
Trial ID
NCT00363896
Start Date
July 1 2006
End Date
May 1 2008
Last Update
January 6 2017
Active Locations (132)
Enter a location and click search to find clinical trials sorted by distance.
1
Almirall Investigational Sites#947
Les Escaldes, Andorra
2
Almirall Investigational Sites#645
Graz, Austria, 8036
3
Almirall Investigational Sites#646
Innsbruck, Austria, 6020
4
Almirall Investigational Sites#644
Linz, Austria, 4010